Identification of collateral sensitivity and evolutionary landscape of chemotherapy-induced drug resistance using cellular barcoding technology
One of the most significant challenges impeding cancer treatment effectiveness is drug resistance. Combining evolutionary understanding with drug resistance can pave the way for the identification of second-line drug options that can overcome drug resistance. Although capecitabine and irinotecan are...
Saved in:
Published in | Frontiers in pharmacology Vol. 14; p. 1178489 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
11.07.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | One of the most significant challenges impeding cancer treatment effectiveness is drug resistance. Combining evolutionary understanding with drug resistance can pave the way for the identification of second-line drug options that can overcome drug resistance. Although capecitabine and irinotecan are commonly used therapeutic agents in the treatment of CRC patients, resistance to these agents is common. The underlying clonal dynamics of resistance to these agents using high-resolution barcode technology and identification of effective second-line drugs in this context remain unclear.
Caco-2 and HT-29 cell lines were barcoded, and then capecitabine and irinotecan resistant derivatives of these cell lines were established. The frequencies of barcodes from resistant cell lines and harvested medium, longitudinally, were determined. Collateral drug sensitivity testing was carried out on resistant Caco-2 and HT-29 cell lines using single agents or drug combinations. The SyngeryFinder tool was used to analyse drug combination testing.
In Caco-2 and HT-29 cell lines, barcode frequency measurements revealed clonal dynamics of capecitabine and irinotecan formed by both pre-existing and
barcodes, indicating the presence of polyclonal drug resistance. The temporal dynamics of clonal evolution in Caco-2 and HT-29 cell lines were demonstrated by longitudinal analysis of pre-existing and
barcodes from harvested medium. In Caco-2 and HT-29 cell lines, collateral drug sensitivity revealed a number of drugs that were effective alone and in combination.
The use of barcoding technology reveals the clonal dynamics of chemotherapy-induced drug resistance not only from harvested cell populations, but also from longitudinal sampling throughout the course of clonal evolution. Second-line drugs that sensitize drug-resistant CRC cell lines are identified through collateral drug testing. |
---|---|
AbstractList | Background:
One of the most significant challenges impeding cancer treatment effectiveness is drug resistance. Combining evolutionary understanding with drug resistance can pave the way for the identification of second-line drug options that can overcome drug resistance. Although capecitabine and irinotecan are commonly used therapeutic agents in the treatment of CRC patients, resistance to these agents is common. The underlying clonal dynamics of resistance to these agents using high-resolution barcode technology and identification of effective second-line drugs in this context remain unclear.
Methods and materials:
Caco-2 and HT-29 cell lines were barcoded, and then capecitabine and irinotecan resistant derivatives of these cell lines were established. The frequencies of barcodes from resistant cell lines and harvested medium, longitudinally, were determined. Collateral drug sensitivity testing was carried out on resistant Caco-2 and HT-29 cell lines using single agents or drug combinations. The SyngeryFinder tool was used to analyse drug combination testing.
Results:
In Caco-2 and HT-29 cell lines, barcode frequency measurements revealed clonal dynamics of capecitabine and irinotecan formed by both pre-existing and
de novo
barcodes, indicating the presence of polyclonal drug resistance. The temporal dynamics of clonal evolution in Caco-2 and HT-29 cell lines were demonstrated by longitudinal analysis of pre-existing and
de novo
barcodes from harvested medium. In Caco-2 and HT-29 cell lines, collateral drug sensitivity revealed a number of drugs that were effective alone and in combination.
Conclusion:
The use of barcoding technology reveals the clonal dynamics of chemotherapy-induced drug resistance not only from harvested cell populations, but also from longitudinal sampling throughout the course of clonal evolution. Second-line drugs that sensitize drug-resistant CRC cell lines are identified through collateral drug testing. Background: One of the most significant challenges impeding cancer treatment effectiveness is drug resistance. Combining evolutionary understanding with drug resistance can pave the way for the identification of second-line drug options that can overcome drug resistance. Although capecitabine and irinotecan are commonly used therapeutic agents in the treatment of CRC patients, resistance to these agents is common. The underlying clonal dynamics of resistance to these agents using high-resolution barcode technology and identification of effective second-line drugs in this context remain unclear.Methods and materials: Caco-2 and HT-29 cell lines were barcoded, and then capecitabine and irinotecan resistant derivatives of these cell lines were established. The frequencies of barcodes from resistant cell lines and harvested medium, longitudinally, were determined. Collateral drug sensitivity testing was carried out on resistant Caco-2 and HT-29 cell lines using single agents or drug combinations. The SyngeryFinder tool was used to analyse drug combination testing.Results: In Caco-2 and HT-29 cell lines, barcode frequency measurements revealed clonal dynamics of capecitabine and irinotecan formed by both pre-existing and de novo barcodes, indicating the presence of polyclonal drug resistance. The temporal dynamics of clonal evolution in Caco-2 and HT-29 cell lines were demonstrated by longitudinal analysis of pre-existing and de novo barcodes from harvested medium. In Caco-2 and HT-29 cell lines, collateral drug sensitivity revealed a number of drugs that were effective alone and in combination.Conclusion: The use of barcoding technology reveals the clonal dynamics of chemotherapy-induced drug resistance not only from harvested cell populations, but also from longitudinal sampling throughout the course of clonal evolution. Second-line drugs that sensitize drug-resistant CRC cell lines are identified through collateral drug testing. One of the most significant challenges impeding cancer treatment effectiveness is drug resistance. Combining evolutionary understanding with drug resistance can pave the way for the identification of second-line drug options that can overcome drug resistance. Although capecitabine and irinotecan are commonly used therapeutic agents in the treatment of CRC patients, resistance to these agents is common. The underlying clonal dynamics of resistance to these agents using high-resolution barcode technology and identification of effective second-line drugs in this context remain unclear. Caco-2 and HT-29 cell lines were barcoded, and then capecitabine and irinotecan resistant derivatives of these cell lines were established. The frequencies of barcodes from resistant cell lines and harvested medium, longitudinally, were determined. Collateral drug sensitivity testing was carried out on resistant Caco-2 and HT-29 cell lines using single agents or drug combinations. The SyngeryFinder tool was used to analyse drug combination testing. In Caco-2 and HT-29 cell lines, barcode frequency measurements revealed clonal dynamics of capecitabine and irinotecan formed by both pre-existing and barcodes, indicating the presence of polyclonal drug resistance. The temporal dynamics of clonal evolution in Caco-2 and HT-29 cell lines were demonstrated by longitudinal analysis of pre-existing and barcodes from harvested medium. In Caco-2 and HT-29 cell lines, collateral drug sensitivity revealed a number of drugs that were effective alone and in combination. The use of barcoding technology reveals the clonal dynamics of chemotherapy-induced drug resistance not only from harvested cell populations, but also from longitudinal sampling throughout the course of clonal evolution. Second-line drugs that sensitize drug-resistant CRC cell lines are identified through collateral drug testing. |
Author | Acar, Ahmet Yilmaz, Kubra Celikbas Danisik, Nurseda |
AuthorAffiliation | Department of Biological Sciences , Middle East Technical University , Universiteler Mah , Ankara , Türkiye |
AuthorAffiliation_xml | – name: Department of Biological Sciences , Middle East Technical University , Universiteler Mah , Ankara , Türkiye |
Author_xml | – sequence: 1 givenname: Nurseda surname: Danisik fullname: Danisik, Nurseda organization: Department of Biological Sciences, Middle East Technical University, Universiteler Mah, Ankara, Türkiye – sequence: 2 givenname: Kubra Celikbas surname: Yilmaz fullname: Yilmaz, Kubra Celikbas organization: Department of Biological Sciences, Middle East Technical University, Universiteler Mah, Ankara, Türkiye – sequence: 3 givenname: Ahmet surname: Acar fullname: Acar, Ahmet organization: Department of Biological Sciences, Middle East Technical University, Universiteler Mah, Ankara, Türkiye |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37497108$$D View this record in MEDLINE/PubMed |
BookMark | eNpVUs1u3CAYtKpUTZrmBXqoOPbiLRhsw6mqov6sFKmX9owwfLaJWNgCXmmfoq9cvLuNEi6gYWb4GM3b6soHD1X1nuANpVx8GvezipsGN3RDSM8ZF6-qG9J1tBacNFfPztfVXUqPuCwqBO3Ym-qa9kz0BPOb6u_WgM92tFplGzwKI9LBOZUhKocS-GSzPdh8RMobBIfglpWn4hG5giSt9nASzbALeS6q_bG23iwaDDJxmVCEZFNWXgNakvUT0uDc4lREg4o6mBXKoGcfXJiO76rXo3IJ7i77bfX729df9z_qh5_ft_dfHmrNOpHrljGqDONN22GOYeAAjIkWEy56TbDRjWaqEQwLyk2P2diKkQFrSiZDyymmt9X27GuCepT7aHflSzIoK09AiJNUMVvtQHZiJNCA6btBMaW5IpQPAxmIaIENPS9en89e-2XYgdEl0BLeC9OXN97OcgoHSTAtA3WkOHy8OMTwZ4GU5c6mNSflISxJNpyVmQu1LdTmTNUxpBRhfHqHYLk2Q56aIddmyEsziujD8wmfJP97QP8B5r-7jg |
CitedBy_id | crossref_primary_10_3389_fcell_2024_1369597 crossref_primary_10_1371_journal_pone_0291942 crossref_primary_10_1038_s41598_023_50443_3 |
Cites_doi | 10.1158/0008-5472.CAN-08-3658 10.1038/nm.4040 10.3390/cancers13194923 10.1038/s41576-019-0114-6 10.1111/cas.12366 10.18632/oncotarget.16723 10.3322/caac.21660 10.1126/scitranslmed.3006609 10.1126/science.aao2774 10.1038/nm.3967 10.1016/j.cell.2016.01.045 10.1038/s41588-020-0675-5 10.15586/jkcvhl.2016.46 10.3389/fimmu.2021.656364 10.1186/gb-2014-15-5-r75 10.1016/j.bbcan.2017.01.003 10.1016/j.clcc.2014.11.002 10.1038/nrc3599 10.1016/j.tim.2015.02.009 10.1038/s41598-017-00791-8 10.1038/s41467-020-15596-z 10.1038/nature11252 10.1038/nrg3922 10.3389/fonc.2014.00086 10.1038/nrc2013 10.1016/j.molonc.2014.06.005 10.1038/nm.3841 10.1016/j.ccell.2019.05.001 10.1158/2159-8290.CD-20-1311 10.1073/PNAS.1806109115 10.1016/j.cell.2018.04.012 10.3390/cancers6031769 10.1126/science.abm5874 10.1038/nmeth.4197 10.1038/s41586-019-1730-1 10.1371/journal.pcbi.1004493 10.1093/bioinformatics/btu170 10.1016/j.dnarep.2021.103177 10.3390/jpm10040180 10.1371/journal.pone.0232565 |
ContentType | Journal Article |
Copyright | Copyright © 2023 Danisik, Yilmaz and Acar. Copyright © 2023 Danisik, Yilmaz and Acar. 2023 Danisik, Yilmaz and Acar |
Copyright_xml | – notice: Copyright © 2023 Danisik, Yilmaz and Acar. – notice: Copyright © 2023 Danisik, Yilmaz and Acar. 2023 Danisik, Yilmaz and Acar |
DBID | NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.3389/fphar.2023.1178489 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef PubMed |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Danisik et al |
EISSN | 1663-9812 |
EndPage | 1178489 |
ExternalDocumentID | oai_doaj_org_article_69f1e2ed76ba4ac8a138bb1b195e4b78 10_3389_fphar_2023_1178489 37497108 |
Genre | Journal Article |
GrantInformation_xml | – fundername: ; |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV DIK EMOBN GROUPED_DOAJ GX1 HYE IAO IEA IHR IHW IPNFZ KQ8 M48 M~E NPM O5R O5S OK1 P2P PGMZT RIG RNS RPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c469t-5443ad48256080eb8ee449501897c10dc2c4a2940938d704f59f4e42663b58303 |
IEDL.DBID | RPM |
ISSN | 1663-9812 |
IngestDate | Tue Oct 22 15:11:45 EDT 2024 Tue Sep 17 21:30:37 EDT 2024 Thu Oct 24 22:52:32 EDT 2024 Thu Sep 26 16:05:19 EDT 2024 Sat Sep 28 08:09:26 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | cancer drug resistance colorectal collateral sensitivity cellular barcoding |
Language | English |
License | Copyright © 2023 Danisik, Yilmaz and Acar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c469t-5443ad48256080eb8ee449501897c10dc2c4a2940938d704f59f4e42663b58303 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Joao M. Fernandes Neto, The Netherlands Cancer Institute (NKI), Netherlands Edited by: Beatriz Carvalho, The Netherlands Cancer Institute (NKI), Netherlands Tejveer Singh, University of Delhi, India |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366361/ |
PMID | 37497108 |
PQID | 2843036365 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_69f1e2ed76ba4ac8a138bb1b195e4b78 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10366361 proquest_miscellaneous_2843036365 crossref_primary_10_3389_fphar_2023_1178489 pubmed_primary_37497108 |
PublicationCentury | 2000 |
PublicationDate | 2023-07-11 |
PublicationDateYYYYMMDD | 2023-07-11 |
PublicationDate_xml | – month: 07 year: 2023 text: 2023-07-11 day: 11 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in pharmacology |
PublicationTitleAlternate | Front Pharmacol |
PublicationYear | 2023 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Davis (B7) 2017; 1867 Dhawan (B8) 2017; 7 Patro (B39) 2017; 14 Vlachogiannis (B35) 2018; 359 Yalcin (B37) 2020; 10 Fang (B9) 2019; 35 Bhang (B3) 2015; 21 (B26) 2020 Sankaran (B30) 2022; 378 Housman (B16) 2014; 6 Turajlic (B33) 2019; 20 Kirkman (B21) 2018; 115 Hata (B13) 2016; 22 Mokhtari (B24) 2017; 8 Zhao (B38) 2016; 165 Guinney (B11) 2015; 21 Imamovic (B18) 2013; 5 Ray (B40) 2021; 106 Gatenby (B10) 2009; 69 Merlo (B23) 2006; 6 Caravagna (B5) 2020; 52 Acar (B1) 2020; 11 Wang (B36) 2018; 173 Burrell (B4) 2014; 8 Vasan (B34) 2019; 575 Porter (B29) 2014; 15 Holohan (B15) 2013; 13 Khalaf (B20) 2021; 12 Gustavsson (B12) 2015; 14 Sung (B32) 2021; 71 Chowdhury (B6) 2021; 13 Bolger (B41) 2014; 30 Hirsch (B14) 2016; 3 Alix-Panabières (B2) 2021; 11 Jekimovs (B19) 2014; 4 Muzny (B25) 2012; 487 Hughes (B17) 2015; 16 Li (B22) 2015; 19 Pál (B28) 2015; 23 Suarez-Arnedo (B31) 2020; 15 Hosoya (B42) 2014; 105 Nichol (B27) 2015; 11 |
References_xml | – volume: 69 start-page: 4894 year: 2009 ident: B10 article-title: Adaptive therapy publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-08-3658 contributor: fullname: Gatenby – volume: 22 start-page: 262 year: 2016 ident: B13 article-title: Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition publication-title: Nat. Med. doi: 10.1038/nm.4040 contributor: fullname: Hata – volume: 13 start-page: 4923 year: 2021 ident: B6 article-title: Implications of intratumor heterogeneity on consensus molecular subtype (Cms) in colorectal cancer publication-title: Cancers (Basel) doi: 10.3390/cancers13194923 contributor: fullname: Chowdhury – volume: 20 start-page: 404 year: 2019 ident: B33 article-title: Resolving genetic heterogeneity in cancer publication-title: Nat. Rev. Genet. doi: 10.1038/s41576-019-0114-6 contributor: fullname: Turajlic – volume: 105 start-page: 370 year: 2014 ident: B42 article-title: Targeting DNA damage response in cancer therapy publication-title: Cancer Sci. doi: 10.1111/cas.12366 contributor: fullname: Hosoya – volume: 8 start-page: 38022 year: 2017 ident: B24 article-title: Combination therapy in combating cancer publication-title: Oncotarget doi: 10.18632/oncotarget.16723 contributor: fullname: Mokhtari – volume: 71 start-page: 209 year: 2021 ident: B32 article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21660 contributor: fullname: Sung – volume: 5 start-page: 204ra132 year: 2013 ident: B18 article-title: Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.3006609 contributor: fullname: Imamovic – volume: 359 start-page: 920 year: 2018 ident: B35 article-title: Patient-derived organoids model treatment response of metastatic gastrointestinal cancers publication-title: Science doi: 10.1126/science.aao2774 contributor: fullname: Vlachogiannis – volume: 21 start-page: 1350 year: 2015 ident: B11 article-title: The consensus molecular subtypes of colorectal cancer publication-title: Nat. Med. doi: 10.1038/nm.3967 contributor: fullname: Guinney – volume: 165 start-page: 234 year: 2016 ident: B38 article-title: Exploiting temporal collateral sensitivity in tumor clonal evolution publication-title: Cell. doi: 10.1016/j.cell.2016.01.045 contributor: fullname: Zhao – volume: 52 start-page: 898 year: 2020 ident: B5 article-title: Subclonal reconstruction of tumors by using machine learning and population genetics publication-title: Nat. Genet. doi: 10.1038/s41588-020-0675-5 contributor: fullname: Caravagna – volume: 3 start-page: 23 year: 2016 ident: B14 article-title: Sequential therapy in metastatic renal cell carcinoma publication-title: J. Kidney Cancer VHL doi: 10.15586/jkcvhl.2016.46 contributor: fullname: Hirsch – volume: 12 start-page: 656364 year: 2021 ident: B20 article-title: Aspects of the tumor microenvironment involved in immune resistance and drug resistance publication-title: Front. Immunol. doi: 10.3389/fimmu.2021.656364 contributor: fullname: Khalaf – volume: 15 start-page: R75 year: 2014 ident: B29 article-title: Lentiviral and targeted cellular barcoding reveals ongoing clonal dynamics of cell lines in vitro and in vivo publication-title: Genome Biol. doi: 10.1186/gb-2014-15-5-r75 contributor: fullname: Porter – volume: 1867 start-page: 151 year: 2017 ident: B7 article-title: Tumor evolution: Linear, branching, neutral or punctuated? publication-title: Biochim. Biophys. Acta Rev. Cancer doi: 10.1016/j.bbcan.2017.01.003 contributor: fullname: Davis – volume-title: Colorectal cancer NICE guideline year: 2020 ident: B26 – volume: 14 start-page: 1 year: 2015 ident: B12 article-title: A review of the evolution of systemic chemotherapy in the management of colorectal cancer publication-title: Clin. Colorectal Cancer doi: 10.1016/j.clcc.2014.11.002 contributor: fullname: Gustavsson – volume: 13 start-page: 714 year: 2013 ident: B15 article-title: Cancer drug resistance: An evolving paradigm publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3599 contributor: fullname: Holohan – volume: 23 start-page: 401 year: 2015 ident: B28 article-title: Collateral sensitivity of antibiotic-resistant microbes publication-title: Trends Microbiol. doi: 10.1016/j.tim.2015.02.009 contributor: fullname: Pál – volume: 7 start-page: 1232 year: 2017 ident: B8 article-title: Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer publication-title: Sci. Rep. doi: 10.1038/s41598-017-00791-8 contributor: fullname: Dhawan – volume: 11 start-page: 1923 year: 2020 ident: B1 article-title: Exploiting evolutionary steering to induce collateral drug sensitivity in cancer publication-title: Nat. Commun. doi: 10.1038/s41467-020-15596-z contributor: fullname: Acar – volume: 487 start-page: 330 year: 2012 ident: B25 article-title: Comprehensive molecular characterization of human colon and rectal cancer publication-title: Nature doi: 10.1038/nature11252 contributor: fullname: Muzny – volume: 16 start-page: 459 year: 2015 ident: B17 article-title: Evolutionary consequences of drug resistance: Shared principles across diverse targets and organisms publication-title: Nat. Rev. Genet. doi: 10.1038/nrg3922 contributor: fullname: Hughes – volume: 4 start-page: 86 year: 2014 ident: B19 article-title: Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: The good, the bad, and the promising publication-title: Front. Oncol. doi: 10.3389/fonc.2014.00086 contributor: fullname: Jekimovs – volume: 6 start-page: 924 year: 2006 ident: B23 article-title: Cancer as an evolutionary and ecological process publication-title: Nat. Rev. Cancer doi: 10.1038/nrc2013 contributor: fullname: Merlo – volume: 8 start-page: 1095 year: 2014 ident: B4 article-title: Tumour heterogeneity and the evolution of polyclonal drug resistance publication-title: Mol. Oncol. doi: 10.1016/j.molonc.2014.06.005 contributor: fullname: Burrell – volume: 21 start-page: 440 year: 2015 ident: B3 article-title: Studying clonal dynamics in response to cancer therapy using high-complexity barcoding publication-title: Nat. Med. doi: 10.1038/nm.3841 contributor: fullname: Bhang – volume: 35 start-page: 851 year: 2019 ident: B9 article-title: Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy publication-title: Cancer Cell. doi: 10.1016/j.ccell.2019.05.001 contributor: fullname: Fang – volume: 11 start-page: 858 year: 2021 ident: B2 article-title: Liquid biopsy: From discovery to clinical application publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-20-1311 contributor: fullname: Alix-Panabières – volume: 115 start-page: E6863 year: 2018 ident: B21 article-title: Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance publication-title: Proc. Natl. Acad. Sci. doi: 10.1073/PNAS.1806109115 contributor: fullname: Kirkman – volume: 19 start-page: 2812 year: 2015 ident: B22 article-title: The irradiated-fibroblasts elicit immune response against tumor in a murine colon cancer model publication-title: Eur. Rev. Med. Pharmacol. Sci. contributor: fullname: Li – volume: 173 start-page: 1413 year: 2018 ident: B36 article-title: An acquired vulnerability of drug-resistant melanoma with therapeutic potential publication-title: Cell. doi: 10.1016/j.cell.2018.04.012 contributor: fullname: Wang – volume: 6 start-page: 1769 year: 2014 ident: B16 article-title: Drug resistance in cancer: An overview publication-title: Cancers (Basel) doi: 10.3390/cancers6031769 contributor: fullname: Housman – volume: 378 start-page: eabm5874 year: 2022 ident: B30 article-title: Cellular barcoding to decipher clonal dynamics in disease publication-title: Science doi: 10.1126/science.abm5874 contributor: fullname: Sankaran – volume: 14 start-page: 417 year: 2017 ident: B39 article-title: Salmon provides fast and bias-aware quantification of transcript expression publication-title: Nat. Methods doi: 10.1038/nmeth.4197 contributor: fullname: Patro – volume: 575 start-page: 299 year: 2019 ident: B34 article-title: A view on drug resistance in cancer publication-title: Nature doi: 10.1038/s41586-019-1730-1 contributor: fullname: Vasan – volume: 11 start-page: e1004493 year: 2015 ident: B27 article-title: Steering evolution with sequential therapy to prevent the emergence of bacterial antibiotic resistance publication-title: PLoS Comput. Biol. doi: 10.1371/journal.pcbi.1004493 contributor: fullname: Nichol – volume: 30 start-page: 2114 year: 2014 ident: B41 article-title: Trimmomatic: a flexible trimmer for Illumina sequence data publication-title: Bioinformatics doi: 10.1093/bioinformatics/btu170 contributor: fullname: Bolger – volume: 106 start-page: 103177 year: 2021 ident: B40 article-title: Understanding the DNA double-strand break repair and its therapeutic implications publication-title: DNA Repair doi: 10.1016/j.dnarep.2021.103177 contributor: fullname: Ray – volume: 10 start-page: 180 year: 2020 ident: B37 article-title: Systems biology and experimental model systems of cancer publication-title: J. Pers. Med. doi: 10.3390/jpm10040180 contributor: fullname: Yalcin – volume: 15 start-page: e0232565 year: 2020 ident: B31 article-title: An image J plugin for the high throughput image analysis of in vitro scratch wound healing assays publication-title: PLoS One doi: 10.1371/journal.pone.0232565 contributor: fullname: Suarez-Arnedo |
SSID | ssj0000399364 |
Score | 2.383703 |
Snippet | One of the most significant challenges impeding cancer treatment effectiveness is drug resistance. Combining evolutionary understanding with drug resistance... Background: One of the most significant challenges impeding cancer treatment effectiveness is drug resistance. Combining evolutionary understanding with drug... Background: One of the most significant challenges impeding cancer treatment effectiveness is drug resistance. Combining evolutionary understanding with drug... |
SourceID | doaj pubmedcentral proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 1178489 |
SubjectTerms | cancer cellular barcoding collateral sensitivity colorectal drug resistance Pharmacology |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQT70gaPlYKGiQUC80apzYsX0ERFUhgXpopd4sO7a7SJCt9gNpfwV_mRk73e4iJC5cd5Os5TfeN8-ZeWbsrWqpAZPKBknpCMNj5ZRKFXKh66Xj2gTa7_jytTu_Ep-v5fXWUV9UE1bsgcvEnXYm8djEoDrvhOu14632nntuZBRelTbf2myJqfwfTLzbidIlgyrMnKbbqSP_z6al95Ra0LnuW0yUDfv_lmX-WSy5xT5nj9jDMW2E92W4j9mDOByw44viO70-gcv7NqrFCRzDxb0j9fqQ_SrtuGncn4NZgow_dR9_hwXVsJdDJMANAeLPMRzdfA25FZiKpPJN0_hj7NhaVyjmMSwChPnqBlC0UyKKEQRUSX8D9EKAKlzB40qaEUHCcrOL_4RdnX26_HhejScxVD3K52VFJnkuCE35ka6j1zEKVFY1Qql6Xoe-6YVrDGrFVgdViyRNEpHIv_VSI0s-ZXvDbIjPGSiTtOmavnUJkxkhnZMiSCk7h1d3SUzYuztU7G0x3LAoVAhDmzG0hKEdMZywDwTc5koyy84fYAjZMYTsv0Jowt7cwW5xcdEEuSHOVguL3E0U33Zywp6VMNj8VKuEwfQM79Y7AbIzlt1vhm_TbODN8Zn4UP7if4z-JdunGaH9Zs6P2N5yvoqvMFFa-td5TfwGiowVrg priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1db9MwFL0aQ0J7QXyT8SEjob2wQJ3Ysf2AECCmCQm0h1XaW-TEdos0ki1tEfkV_GXuddKOou21TZ0m9zjnHOfea4DXKqcCTEobJKcjDPepVSqkyIW2lpZr42i949v34ngqvp7Jsx1Yb3c03sDFtdaO9pOadudvf1_2H3DCvyfHiXz7LlzMLbX2zHJ6BamFNrfgdibQqVMq3yj345OZ2Dh2lOJItKlBchvqaG4YZg_u5EoYJGG9RVuxu_91kvT_zMp_qOroHtwdNSb7OIDiPuz45gEcnAxNqvtDdnpVc7U4ZAfs5Kp9df8Q_gy1u2FczGNtYBEsVKp8zhaU8D7sOMFs45j_NWLXdj2LdcOUURV_NPc_x_KuPkXnjxhyzHWrGUOHT6oV4cYo7X7G6O0BpcOyCqddS2zKlpsl_0cwPfpy-vk4HbdtSGv02suUOupZJzSJKT3xlfZeoA2bYNxVzSeuzmphM4PGMtdOTUSQJghPSiGvpEZKfQy7Tdv4p8CUCdoUWZ3bgMpHSGulcFLKwuLRRRAJvFlHpbwYunOU6GoonGUMZ0nhLMdwJvCJArc5kjprxw_ablaOE7UsTOA-804VlRW21pbnuqp4xY30olI6gVfrsJc4E-kG2ca3q0WJRE96IC9kAk8GGGxOtYZRAnoLIFv_Zfub5sc8dvvmOCYOyvdvHPQZ7NFl0ooz589hd9mt_AuUSsvqZcT_X0A9EiY priority: 102 providerName: Scholars Portal |
Title | Identification of collateral sensitivity and evolutionary landscape of chemotherapy-induced drug resistance using cellular barcoding technology |
URI | https://www.ncbi.nlm.nih.gov/pubmed/37497108 https://search.proquest.com/docview/2843036365 https://pubmed.ncbi.nlm.nih.gov/PMC10366361 https://doaj.org/article/69f1e2ed76ba4ac8a138bb1b195e4b78 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECWSnHoputddAhYocmkUm-Ii8tgGDYICLnxIgNwIUiLtALFkeCngr-gvd4aSHLvoqRcdJBES9IZ684YzQ0I-FxwLMDFtEJWOMCxkrihiBlzoSumYNhXGO8Y_1fWt-HEn746I6mthUtJ-6e8v6of5RX0_S7mVi3k57PPEhpPxJYPfruKKDY_JMVjonkZP_1_kXCXaChlQYGYYFzOHvT9zjmuUWuCe7nsslJr1_8vD_DtRco95rp6Rp53LSL-2r_acHIX6BTmbtD2nt-f05rGEanVOz-jksRv19iX53Zbixi42R5tIE_ZYefxAV5i_3m4gQV1d0fCrM0W33NJUBowJUmnQLMy7aq1tBkIeTKKi1XIzpSDY0QkF66GYRT-luBiA2a3UwyxqkBzpehfBf0Vur77fXF5n3S4MWQnSeZ1hgzxXCY2-kR4Fr0MQoKpGAGNRslFV5qVwuQGdyHVVjESUJoqAxM-91MCQr8lJ3dThLaGFidqovOQugiMjpHNSVFJK5eBuFcWAfOlRsYu22YYFkYIY2oShRQxth-GAfEPgdndio-x0ollObWcuVpnIQh6qQnknXKkd49p75pmRQfhCD8inHnYLEws_kKtDs1lZ4G2kd67kgLxpzWD3KF4IA64ZjNYHBnLwLodXwJZT8-7edt_9_9D35Al-B4wwM_aBnKyXm_ARXKO1P00hBTiOhT5Ns-IPw5wVuA |
link.rule.ids | 230,315,730,783,787,867,888,2109,24330,27936,27937,53804,53806 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjpswFLWm00W76fuRPl2pmk2HBINtzLIddZS2k1EWGXV2yAaTRJ1AREil9Cf6y73XQCYZddNuAQswx9xz7XOPCXkfhViAibJBzHR4zKynoyj3IBbqVGim4gznO0bncnjBv16KywMiu1oYJ9pPzbxfXC36xXzmtJXLRTrodGKD8eiEwW9XhpINbpHbMGB9vpOluz8wRl3JmxoZyMHiQb6caXT_DEJcpVQcd3XfiUPOrv9vHPOmVHIn9pzeJ9-7p24kJz_669r00183DB3__bUekHstHaUfm_MPyYEtHpGjceNnvTmmk-vyrNUxPaLja6frzWPyuynzzdt5P1rm1OEKq5qv6Aq18c3mFFQXGbU_W5jrakNdiTGKr1yjmV20lWAbb15kALeMZtV6Siu7QoILyKSo0J9SXGhA5Sw1MEJLDLy03q4OPCEXp58nJ0Ov3eHBSyEtrz0039MZV8i7lG-NspZDxuYDRKKU-VkapFwHMeSgocoin-cizrlFUhEaoSD6PiWHRVnY54RGca5iGaShzoEkcaG14JkQQmq4Wua8Rz503ztZNkYeCSRAiI7EoSNBdCQtOnrkE0JieyWacLsDZTVN2m-WyDhnNrBZJI3mOlWahcoYZlgsLDeR6pF3HaASGLTYQbqw5XqVACdA6hBK0SPPGoBtbxVGPAbaB63VHvT2nmX_DADKGYN3AHrx_03fkjvDyegsOfty_u0luYt9gjPZjL0ih3W1tq-BgtXmjRtvfwCV7jYK |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECXaFCh66d7UXVmgyKWRZVokRR3btEa6JPAhAQL0IHC1jcayIdsF3J_oL3dGi2MHPeUqkdD2qHlDvnkk5H2aYAEmygYx0-EZ85FO0xBBLNRWaKYyh_MdJ6fy-Jx_uxAXjapy0cgqC2sm3eJy2i0m40pbOZ_auNWJxcOTIwa_XZlIFs9diG-TOzBoe3IrU6_-whh5Ja_rZCAPy-IwH2t0AO0nuFKpOO7svhWLKsv-__HM63LJrfgzeEB-tndey05-dVdL07V_rpk63uzRHpL7DS2lH-s2j8gtXzwmB8Pa13p9SM-uyrQWh_SADq8cr9dPyN-63Dc08390FmiFL6xuvqQL1MjXm1RQXTjqfzdw1-WaVqXGKMKqOo39tKkIW0eTwgHsHHXlakRLv0CiCwilqNQfUVxwQAUtNTBSZxiA6XKzSvCUnA--nB0dR81OD5GF9HwZoQmfdlwh_1I9b5T3HDK3HkAltaznbN9y3c8gF02US3s8iCxwj-QiMUJBFH5G9opZ4Z8TmmZBZbJvEx2ALHGhteBOCCE1tJaBd8iH9pvn89rQI4dECBGSVwjJESF5g5AO-YSw2LREM-7qwKwc5c13y2UWmO97l0qjubZKs0QZwwzLhOcmVR3yrgVVDoMXX5Au_Gy1yIEbIIVIpOiQ_Rpkm0slKc-A_kFvtQO_nXvZPQOgqgzCWxC9uHnXt-Tu8PMg__H19PtLcg9fCU5oM_aK7C3LlX8NTGxp3lRD7h8RsjiK |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+of+collateral+sensitivity+and+evolutionary+landscape+of+chemotherapy-induced+drug+resistance+using+cellular+barcoding+technology&rft.jtitle=Frontiers+in+pharmacology&rft.au=Danisik%2C+Nurseda&rft.au=Yilmaz%2C+Kubra+Celikbas&rft.au=Acar%2C+Ahmet&rft.date=2023-07-11&rft.issn=1663-9812&rft.eissn=1663-9812&rft.volume=14&rft.spage=1178489&rft_id=info:doi/10.3389%2Ffphar.2023.1178489&rft_id=info%3Apmid%2F37497108&rft.externalDocID=37497108 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |